RLY-2608: clinical trials recruiting now

Fewer than 3 recruiting trials found.

1

Recruiting trials

7

Conditions studied

18

US states with sites

5

Countries

Phase breakdown

Phase 1 1

Conditions being studied

Condition	Trials
Advanced Breast Cancer	1
Breast Cancer	1
HER2-negative Breast Cancer	1
Metastatic Breast Cancer	1
PIK3CA Mutation	1
Solid Tumor, Adult	1
Unresectable Solid Tumor	1

Recruiting trials involving RLY-2608

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
NCT05216432 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 37 locations

Common questions

How many recruiting trials involve RLY-2608?

1 recruiting trial across 7 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.